

MARKSANS PHARMA LIMITED

Read Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri (West), Mumbai-400053
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2013

PART 1

Sr. No.	PARTICULARS	3 MONTHS ENDED			9 MONTHS ENDED			Previous Year ended
		31.12.2013 (UNAUDITED)	30.09.2013 (UNAUDITED)	31.12.2012 (UNAUDITED)	31.12.2013 (UNAUDITED)	31.12.2012 (UNAUDITED)	31.03.2013 (AUDITED)	
1	Income							
a)	Net Sales/ Income from Operations (Net of excise duty)	8,073.97	7,851.37	4,933.37	23,127.42	13,362.61	19,229.70	
b)	Other Operating Income	-	-	18.53	270.38	441.37	471.18	
	Total Income from operations (net)	8,073.97	7,851.37	4,951.90	23,397.80	13,803.98	19,646.88	
2	Expenses							
a)	Cost of Material Consumed	3,723.86	3,245.68	2,082.44	9,433.03	5,466.11	6,595.75	
b)	Purchase of Stock - in- trade	754.54	674.01	917.06	2,210.66	1,571.80	2,755.31	
c)	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(152.68)	(45.23)	(1.51)	(42.12)	(4.33)	919.31	
d)	Employee benefits expense	479.93	478.42	348.15	1,426.41	1,053.95	1,539.25	
e)	Depreciation and amortisation expense	224.90	223.97	219.32	689.33	651.96	870.33	
f)	Other expenses	1,058.09	1,047.71	350.69	3,014.66	4,092.28	2,993.19	
	Total Expenses	6,088.64	5,624.56	3,916.15	16,711.97	12,831.77	15,673.14	
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	1,985.33	2,226.81	1,035.75	6,685.83	972.21	3,973.74	
4	Other Income	-	-	-	-	-	-	
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	1,985.33	2,226.81	1,035.75	6,685.83	972.21	3,973.74	
6	Finance cost	167.02	254.12	245.39	1,174.05	714.86	1,013.24	
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	1,818.31	1,972.69	790.36	5,511.78	257.35	2,960.50	
8	Exceptional items	-	-	-	-	-	-	
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	1,818.31	1,972.69	790.36	5,511.78	257.35	2,960.50	
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	250.00	193.04	790.36	485.00	-	(997.77)	
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	1,568.31	1,779.65	790.36	5,026.78	257.35	3,958.27	
12	Less: Extraordinary Item	-	-	-	-	-	-	
13	Net Profit/ (Loss) for the period (11-12)	1,568.31	1,779.65	790.36	5,026.78	257.35	3,958.27	
14	Paid up Equity Share Capital (Face Value Re. 1 each)	3,853.07	3,853.07	3,853.07	3,853.07	3,853.07	3,853.07	
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting Year						5,794.56	
16 a)	Earnings Per Share (before extraordinary items Rs.)- Basic	0.41	0.46	0.21	1.30	0.07	1.03	
	Diluted	0.41	0.46	0.21	1.30	0.07	1.03	
b)	Earnings Per Share(after extraordinary items- Rs.)- Basic	0.41	0.46	0.21	1.30	0.07	1.03	
	Diluted	0.41	0.46	0.21	1.30	0.07	1.03	
PART 2								
A PARTICULARS OF SHAREHOLDING								
1	Public Shareholding:							
	- Number of Shares	187,815,471	187,815,471	189,824,114	187,815,471	189,824,114	188,634,244	
	- Percentage of Holding	48.75%	48.75%	49.27%	48.75%	49.27%	48.96%	
2	Promoters and Promoter group Shareholdings	197,491,733	197,491,733	195,483,090	197,491,733	195,483,090	196,672,960	
	a) Pledged/Encumbered							
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A	N/A	N/A	
	b) Non-encumbered							
	- Number of Shares	197,491,733	197,491,733	195,483,090	197,491,733	195,483,090	196,672,960	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%	100%	
	- Percentage of Holding (as a % of the total share capital of the Company)	51.25%	51.25%	50.73%	51.25%	50.73%	51.04%	

(₹ in Lakhs)



[Handwritten Signature]

B INVESTOR COMPLAINTS	3 MONTHS ENDED 31.12.2013
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	-
Remaining unresolved at the end of the quarter	Nil

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 03.02.2014.
- 2 The Company has published its consolidated financial statements separately. On consolidated basis, it has achieved revenue of ₹ 47,390.65 Lacs and PAT of ₹ 6,127.79 Lacs for the 9 months ended 31.12.2013.
- 3 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 4 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 5 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai.
Date: 03.02.2014
www.marksanspharma.com



(Handwritten Signature)
For MARKSANS PHARMA LIMITED
MARK SALDANHA
 Managing Director.